Privia Health Group, Inc. (PRVA): Results of Operations and Financial Condition
Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for
How this was made
The 30-second read
Why it matters
The filing provides fresh, decision-relevant datapoints: 2Q’26 financial results, key operating metrics (implemented providers, attributed lives, practice collections), and raised FY2026 guidance ranges for revenue and profitability metrics, plus a stated expected adjusted EBITDA to free cash flow conversion range.
Market read
Traders can update PRVA earnings models immediately using the raised FY2026 ranges and the disclosed operating KPIs that typically drive valuation for this business model.
What to watch
Net income includes sizable non-cash stock compensation; traders may focus more on cash flow conversion and provider growth quality (implemented providers and attributed lives) than headline earnings.
Background
The 8-K (Item 2.02) includes an earnings release (Exhibit 99.1) covering 2Q’26 results and updated FY2026 guidance for Privia Health Group.
Ticker impact
Privia reported 2Q’26 results and raised full-year 2026 guidance, including higher revenue, care margin, platform contribution, and adjusted EBITDA ranges.
Near-term bias to the upside as traders reprice FY2026 expectations; follow-through depends on whether the raised ranges are viewed as credible versus prior guidance.
The filing discloses specific quarterly performance and explicit updated full-year guidance ranges for multiple key operating and financial metrics, which typically drives earnings-model updates and sentiment.
Market effects
Reinforces demand and margin expansion narratives in physician enablement/value-based care platforms, potentially supporting peer sentiment.
Limited direct regional impact; company-specific guidance update.
Primarily US healthcare services read-through; minimal global macro linkage.
Counterpoint
Guidance includes non-GAAP framing and relies on assumptions around MSSP cash settlement timing, so free-cash-flow conversion may be less smooth than adjusted EBITDA implies.
Key entities
- public_companyPrivia Health Group, Inc.
Nasdaq-listed physician enablement company reporting 2Q’26 results and raising FY2026 guidance in an SEC 8-K.
